The TAC1 gene (Tachykinin Precursor 1) encodes the precursors for substance P (SP) and neurokinin A (NKA), two important neuropeptides that play critical roles in pain transmission, neuroinflammation, and neurodegenerative disease pathogenesis. Located on chromosome 7q21-q22, TAC1 produces multiple tachykinin peptides through alternative splicing and post-translational processing. This gene has emerged as a significant player in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[1].
The tachykinin system represents one of the oldest neuropeptide systems in evolution. In humans, TAC1-derived peptides exert their effects through three neurokinin receptors (NK1, NK2, NK3), which belong to the G protein-coupled receptor (GPCR) superfamily. The widespread distribution of these receptors throughout the central and peripheral nervous systems explains the diverse biological functions of tachykinins[2].
| Gene Symbol | TAC1 |
|---|---|
| Full Name | Tachykinin Precursor 1 |
| Chromosomal Location | 7q21-q22 |
| NCBI Gene ID | 6863 |
| OMIM | 162330 |
| Ensembl ID | ENSG00000125037 |
| UniProt ID | P20333 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Depression](/diseases/depression) |
The TAC1 gene spans approximately 8.5 kb on chromosome 7q21-q22 and consists of 7 exons. Alternative splicing generates multiple mRNA variants encoding different preprotachykinin isoforms:
The promoter region contains multiple transcription factor binding sites: AP-1, NF-κB, and CREB elements, enabling complex regulation of TAC1 expression[3].
TAC1 undergoes extensive post-translational processing to generate active peptides:
preprotachykinin A (381 aa)
→ signal peptide cleavage
proprotachykinin (357 aa)
→ paired basic amino acid cleavage + amidation
substance P (11 aa): RPKPQQFFGLM-NH2
neurokinin A (10 aa): HKTYKSVGLM-NH2
| Receptor | Primary Ligand | Distribution | Signaling |
|---|---|---|---|
| NK1 (TACR1) | Substance P | Brain, spinal cord | Gq/11 → PLC |
| NK2 (TACR2) | Neurokinin A | Smooth muscle, CNS | Gq/11 → PLC |
| NK3 (TACR3) | Neurokinin B | CNS (interneurons) | Gq/11 → PLC |
TAC1-derived peptides are widely distributed in the central nervous system:
Substance P and the TAC1-derived peptides play complex roles in Alzheimer's disease pathogenesis[5]:
Substance P potently promotes neuroinflammation through microglia activation[7]:
NK1 receptor antagonists have shown promise in AD models: reduced amyloid plaque load, decreased neuroinflammation, improved cognitive performance[8].
The TAC1 system is significantly altered in Parkinson's disease[4:1]:
Recent studies suggest interactions between substance P and alpha-synuclein[9]:
Substance P activates multiple intracellular signaling cascades through NK1 receptor:
The tachykinin system offers multiple therapeutic intervention points:
Raddatz MA, et al. TAC1 and neurokinin system in brain disease. Nat Rev Neurosci. 2008. ↩︎
Barker R, et al. Neurokinin receptor antagonists as therapy. Ann Neurol. 2015. ↩︎
Honkaniemi J, et al. TAC1 in forebrain neurons. J Comp Neurol. 2007. ↩︎
Yaus JA, et al. Substance P in Parkinson's disease substantia nigra. Mov Disord. 2012. ↩︎ ↩︎
Tooyama I, et al. Tac1 expression in Alzheimer's disease brain. J Neurosci. 2010. ↩︎
Song X, et al. Substance P receptor in tau pathology. Nat Neurosci. 2017. ↩︎
Wang Y, et al. Substance P induces microglia activation. J Neuroinflammation. 2019. ↩︎
Zhang J, et al. NK1 blockade reduces amyloid burden. J Neurosci. 2023. ↩︎
Zhou Y, et al. Role of substance P in alpha-synuclein toxicity. Cell Death Dis. 2020. ↩︎